P1, N=10, Not yet recruiting, University of Texas Southwestern Medical Center

Postoperatively, the patient received adjuvant chemotherapy with the AIM (doxorubicin, ifosfamide, and mesna) regimen. Given the extreme rarity of PRSS, we discuss the diagnostic challenges, molecular characteristics, and treatment approach adopted at our institution, contributing to the limited but growing body of knowledge on this rare entity.

P4, N=216, Not yet recruiting, Xuanwu Hospital Capital Medical University; Xuanwu Hospital Capital Medical University

P=N/A, N=10, Recruiting, Erasme University Hospital

P1, N=44, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Feb 2030 --> Jan 2031 | Trial primary completion date: Feb 2030 --> Jan 2031

P2, N=120, Completed, Faraday Pharmaceuticals, Inc. | Phase classification: P2a --> P2

P2, N=79, Active, not recruiting, University of Edinburgh | Recruiting --> Active, not recruiting | N=206 --> 79 | Trial completion date: Dec 2025 --> Nov 2026 | Trial primary completion date: Dec 2024 --> Dec 2025

P2, N=0, Withdrawn, University of Edinburgh | N=120 --> 0 | Suspended --> Withdrawn

P2, N=60, Recruiting, UConn Health | Trial completion date: Jul 2027 --> Feb 2028 | Trial primary completion date: Sep 2025 --> Mar 2027

P=N/A, N=77, Completed, Ege University

Mitochondrial ROS were found to be essential in mediating Nrf2-dependent thermotolerance, because MitoQ treatment prior to exposure to 40 °C reduced Nrf2 levels and dissipated the subsequent protective effect of thermotolerance against toxicity at 42 °C. Our study demonstrates that specific sources of ROS had biologically different implications in activating Nrf2, underlining potential therapeutic targets that may contribute to thermotolerance in anticancer treatments.

P1/2, N=49, Active, not recruiting, Nacuity Pharmaceuticals, Inc. | Trial completion date: Aug 2025 --> Apr 2026